110 related articles for article (PubMed ID: 3358635)
21. Monitoring uptake of ellipticine and its fluorescence lifetime in relation to the cell cycle phase by flow cytometry.
Sailer BL; Valdez JG; Steinkamp JA; Darzynkiewicz Z; Crissman HA
Exp Cell Res; 1997 Oct; 236(1):259-67. PubMed ID: 9344606
[TBL] [Abstract][Full Text] [Related]
22. Mutagenicity and cytotoxicity of five antitumor ellipticines in mammalian cells and their structure-activity relationships in Salmonella.
DeMarini DM; Cros S; Paoletti C; Lecointe P; Hsie AW
Cancer Res; 1983 Aug; 43(8):3544-52. PubMed ID: 6344986
[TBL] [Abstract][Full Text] [Related]
23. Isolation and properties of Chinese hamster lung cells resistant to ellipticine derivatives.
Salles B; Charcosset JY; Jacquemin-Sablon A
Cancer Treat Rep; 1982 Feb; 66(2):327-38. PubMed ID: 7055817
[TBL] [Abstract][Full Text] [Related]
24. Bioactivation of the antitumor drugs 9-hydroxyellipticine and derivatives by a peroxidase-hydrogen peroxide system.
Auclair C; Paoletti C
J Med Chem; 1981 Mar; 24(3):289-95. PubMed ID: 7265115
[TBL] [Abstract][Full Text] [Related]
25. Comparative study of the incorporation of ellipticine-esters into low density lipoprotein (LDL) and selective cell uptake of drug--LDL complex via the LDL receptor pathway in vitro.
Samadi-Baboli M; Favre G; Bernadou J; Berg D; Soula G
Biochem Pharmacol; 1990 Jul; 40(2):203-12. PubMed ID: 2375762
[TBL] [Abstract][Full Text] [Related]
26. Effect of membrane potential on the cellular uptake of 2-N-methyl-ellipticinium by L1210 cells.
Charcosset JY; Jacquemin-Sablon A; Le Pecq JB
Biochem Pharmacol; 1984 Jul; 33(14):2271-5. PubMed ID: 6466349
[TBL] [Abstract][Full Text] [Related]
27. Peroxidase-catalysed covalent binding of the antitumor drug 2N-methyl-9-hydroxy-ellipticine to proteins.
Auclair C; Meunier B; Paoletti C
Biochem Pharmacol; 1983 Dec; 32(24):3883-6. PubMed ID: 6661265
[No Abstract] [Full Text] [Related]
28. Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha1-acid glycoprotein binding.
Curtin NJ; Bowman KJ; Turner RN; Huang B; Loughlin PJ; Calvert AH; Golding BT; Griffin RJ; Newell DR
Br J Cancer; 1999 Aug; 80(11):1738-46. PubMed ID: 10468290
[TBL] [Abstract][Full Text] [Related]
29. Structure-activity relationships of alkylphosphocholine derivatives: antineoplastic action on brain tumor cell lines in vitro.
Jendrossek V; Hammersen K; Erdlenbruch B; Kugler W; Krügener R; Eibl H; Lakomek M
Cancer Chemother Pharmacol; 2002 Jul; 50(1):71-9. PubMed ID: 12111115
[TBL] [Abstract][Full Text] [Related]
30. Structure-activity relationships in a series of newly synthesized 1-amino-substituted ellipticine derivatives.
Ducrocq C; Wendling F; Tourbez-Perrin M; Rivalle C; Tambourin P; Pochon F; Bisagni E; Chermann JC
J Med Chem; 1980 Nov; 23(11):1212-6. PubMed ID: 7452670
[TBL] [Abstract][Full Text] [Related]
31. Effects of ellipticine on cell survival and cell cycle progression in cultured mammalian cells.
Traganos F; Staiano-Coico L; Darzynkiewicz Z; Melamed MR
Cancer Res; 1980 Jul; 40(7):2390-9. PubMed ID: 6155993
[TBL] [Abstract][Full Text] [Related]
32. Identification of the glucuronide and glutathione conjugates of the antitumor drug N2-methyl-9-hydroxyellipticinium acetate (Celiptium). Comparative disposition of this drug with its olivacinium isomer in rat bile.
Maftouh M; Monsarrat B; Rao RC; Meunier B; Paoletti C
Drug Metab Dispos; 1984; 12(1):111-9. PubMed ID: 6141901
[TBL] [Abstract][Full Text] [Related]
33. Effects of growth factors on the antiproliferative activity of tumor necrosis factors.
Sugarman BJ; Lewis GD; Eessalu TE; Aggarwal BB; Shepard HM
Cancer Res; 1987 Feb; 47(3):780-6. PubMed ID: 3802082
[TBL] [Abstract][Full Text] [Related]
34. Microbial transformations of natural antitumor agents: use of solubilizing agents to improve yields of hydroxylated ellipticines.
Chien MM; Rosazza JP
Appl Environ Microbiol; 1980 Oct; 40(4):741-5. PubMed ID: 7425624
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate.
Li WW; Tong WP; Bertino JR
Clin Cancer Res; 1995 Jun; 1(6):631-6. PubMed ID: 9816025
[TBL] [Abstract][Full Text] [Related]
36. Microbial transformations of natural antitumor agents. VIII. Formation of 8- and 9-hydroxyellipticines.
Chien MM; Rosazza JP
Drug Metab Dispos; 1979; 7(4):211-4. PubMed ID: 39722
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of 2-methyl-9-hydroxyellipticinium acetate (NSC-264137) in cancer patients (phase I study).
Gouyette A; Huertas D; Droz JP; Rouesse J; Amiel JL
Eur J Cancer Clin Oncol; 1982 Dec; 18(12):1285-92. PubMed ID: 6891926
[TBL] [Abstract][Full Text] [Related]
38. The DNA-association and biological activity of a new bis(14-thiadaunomycin).
Skorobogaty A; Brownlee RT; Chandler CJ; Kyratzis I; Phillips DR; Reiss JA; Trist H
Anticancer Drug Des; 1988 Jun; 3(1):41-56. PubMed ID: 3382506
[TBL] [Abstract][Full Text] [Related]
39. Effects of new antitumor bifunctional intercalators derived from 7H-pyridocarbazole on sensitive and resistant L 1210 cells.
Esnault C; Roques BP; Jacquemin-Sablon A; Le Pecq JB
Cancer Res; 1984 Oct; 44(10):4355-60. PubMed ID: 6467197
[TBL] [Abstract][Full Text] [Related]
40. Ellipticine derivatives interacting with model membranes. Influence of quaternarization of nitrogen-2.
Lempereur L; Sautereau AM; Tocanne JF; Laneelle G
Biochem Pharmacol; 1984 Aug; 33(15):2499-503. PubMed ID: 6466364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
